Dr. Lode Swinnen

Maria Baer is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Baer is rated as an Elite provider by MediFind in the treatment of Acute Myeloid Leukemia (AML). Her top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Promyelocytic Leukemia, Bone Marrow Aspiration, and Splenectomy. Dr. Baer is currently accepting new patients.

Dr. Ivana Gojo is a Hematologist/Oncologist in Baltimore. Her clinical focus is on diagnosis and management of patients with acute leukemias (AML, ALL) and other myeloid malignancies (MDS, MPNs, CML), with emphasis on the development of novel therapeutic approaches for these diseases. She is nationally and internationally recognized expert in clinical translation of novel therapeutics for acute leukemias and principal investigator on multiple multi-center investigator-initiated studies. Dr. Gojo joined the Johns Hopkins faculty in 2012 as the Co-Director of Leukemia Drug Development Program. She has served on the National Cancer Institute (NCI) Investigational Drug Steering Committee since 2014. Dr. Gojo received a Service Star Award from Johns Hopkins Medicine Service Excellence in 2018 for her exemplary care of leukemia patients. Dr. Gojo contributed to the clinical translational and drug development effort of multiple novel agents targeting pathogenic pathways in patients with acute leukemia. Her research efforts are now concentrated on the development and integration of novel immunotherapies into therapeutic armamentarium for patients with acute leukemia. She mentors basic and clinical research fellows and junior faculty on the development and design of novel clinical trials and mechanistic laboratory studies associated with these trials. She served as a leukemia team leader on the National Institute of Health (NIH)/NCI N01 grant (Phase II consortium) (2009-2011), and is co-principal investigator (PI) on the Experimental Therapeutics (ET)-Clinical Trial Network (CTN) UM1 grant supporting early clinical trials. Dr. Gojo has served on the National Comprehensive Cancer Network guideline panel for AML since 2019, Myeloid Growth Factor guideline panel since 2015 and previously served on the MPNs guideline panel (2016-2019). She has extensive experience in the regulatory aspects of drug development and served as the Chair (2015-2016) and Co-Chair (2014-2015) of the Cancer Research Review Committee at Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins, and serves as a member of the SKCCC Biostatistics Core Advisory Committee and SKCCC Clinical Research Office Coordinating Center Oversight Committee. Dr. Gojo is rated as a Distinguished provider by MediFind in the treatment of Acute Myeloid Leukemia (AML). Her top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Mark J. Levis, M.D., Ph.D., professor of oncology, medicine and pharmacology in the Division of Hematologic Malignancies at the Johns Hopkins University School of Medicine, co-directs the Hematologic Malignancies and Bone Marrow Transplantation Program and directs the Adult Leukemia Service at the Johns Hopkins Sidney Kimmel Cancer Center. In addition to his role within the Kimmel Cancer Center, he serves on the faculty for the Johns Hopkins Graduate Training Program in Cellular and Molecular Medicine, a Ph.D. program that prepares scientists to conduct laboratory research at the cellular and molecular level that is designed to have a direct impact on the understanding of human diseases. Dr. Levis has expertise in acute and chronic myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndromes. Dr. Levis received his medical degree at the University of California, San Francisco School of Medicine, where he also earned his Ph.D. in Biochemistry. He completed a residency in internal medicine at Johns Hopkins, followed by fellowships in medical oncology. Dr. Levis is a member of the American Society of Hematology, the American Society of Clinical Oncology and the European Hematology Association. He is an ad hoc member of the Oncology Drug Advisory Committee, as well as an ad hoc manuscript referee for peer-reviewed journals such as New England Journal of Medicine; Leukemia; Clinical Cancer Research; and The American Journal of Hematology. Dr. Levis has earned numerous awards, such as the Daniel Nathans Research Award from Johns Hopkins University, the Osler Housestaff Teaching Award, the Director's Teaching Award in Clinical Science, and the Advanced Clinical Research Award from the American Society of Clinical Oncology. Dr. Levis’ laboratory research focuses on the development of molecularly-targeted therapies for leukemia. He is actively involved in the pre-clinical and clinical development of small molecule inhibitors of protein kinases, including FLT3. The research involves studying the biochemical effects of these inhibitors on samples taken from leukemia patients, with the broad goal of identifying and validating novel molecular therapeutic targets in these hematopoietic malignancies. While Dr. Levis plays a key role in the pre-clinical development of these therapies, he is particularly interested in translating this research to the bedside of his patients by using correlative studies to incorporate these novel therapies into existing treatments. In addition to his work in both the clinic and the laboratory, Dr. Levis has also conducted talks, mentorship and teaching lectures, and published extensively in the top journals in his field, including Leukemia; Blood; and the New England Journal of Medicine. Dr. Levis is rated as an Elite provider by MediFind in the treatment of Acute Myeloid Leukemia (AML). His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Acute Promyelocytic Leukemia, Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Aspiration.